OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager

OSE Immunotherapeutics SA

PAR:OSE

Watchlist

Dividends

Discount Rate

Price: 9.28 EUR 0.22% Market Closed

Market Cap: 201.9m EUR

Have any thoughts about
OSE Immunotherapeutics SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 9.28 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

OSE Alert

OSE Immunotherapeutics SA

9.28

+0.02 (+0.22%)

52 Week Range	3.2 10.74
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

OSE Immunotherapeutics SA

What unique competitive advantages
does OSE Immunotherapeutics SA hold over its rivals?

What risks and challenges
does OSE Immunotherapeutics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of OSE Immunotherapeutics SA.

What unique competitive advantages
does OSE Immunotherapeutics SA hold over its rivals?

What risks and challenges
does OSE Immunotherapeutics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for OSE Immunotherapeutics SA.

Provide P/S
for OSE Immunotherapeutics SA.

Provide P/E
for OSE Immunotherapeutics SA.

Provide P/OCF
for OSE Immunotherapeutics SA.

Provide P/FCFE
for OSE Immunotherapeutics SA.

Provide P/B
for OSE Immunotherapeutics SA.

Provide EV/S
for OSE Immunotherapeutics SA.

Provide EV/GP
for OSE Immunotherapeutics SA.

Provide EV/EBITDA
for OSE Immunotherapeutics SA.

Provide EV/EBIT
for OSE Immunotherapeutics SA.

Provide EV/OCF
for OSE Immunotherapeutics SA.

Provide EV/FCFF
for OSE Immunotherapeutics SA.

Provide EV/IC
for OSE Immunotherapeutics SA.

Show me price targets
for OSE Immunotherapeutics SA made by professional analysts.

What are the Revenue projections
for OSE Immunotherapeutics SA?

How accurate were the past Revenue estimates
for OSE Immunotherapeutics SA?

What are the Net Income projections
for OSE Immunotherapeutics SA?

How accurate were the past Net Income estimates
for OSE Immunotherapeutics SA?

What are the EPS projections
for OSE Immunotherapeutics SA?

How accurate were the past EPS estimates
for OSE Immunotherapeutics SA?

What are the EBIT projections
for OSE Immunotherapeutics SA?

How accurate were the past EBIT estimates
for OSE Immunotherapeutics SA?

Compare the revenue forecasts
for OSE Immunotherapeutics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of OSE Immunotherapeutics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of OSE Immunotherapeutics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of OSE Immunotherapeutics SA compared to its peers.

Compare the P/E ratios
of OSE Immunotherapeutics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing OSE Immunotherapeutics SA with its peers.

Analyze the financial leverage
of OSE Immunotherapeutics SA compared to its main competitors.

Show all profitability ratios
for OSE Immunotherapeutics SA.

Provide ROE
for OSE Immunotherapeutics SA.

Provide ROA
for OSE Immunotherapeutics SA.

Provide ROIC
for OSE Immunotherapeutics SA.

Provide ROCE
for OSE Immunotherapeutics SA.

Provide Gross Margin
for OSE Immunotherapeutics SA.

Provide Operating Margin
for OSE Immunotherapeutics SA.

Provide Net Margin
for OSE Immunotherapeutics SA.

Provide FCF Margin
for OSE Immunotherapeutics SA.

Show all solvency ratios
for OSE Immunotherapeutics SA.

Provide D/E Ratio
for OSE Immunotherapeutics SA.

Provide D/A Ratio
for OSE Immunotherapeutics SA.

Provide Interest Coverage Ratio
for OSE Immunotherapeutics SA.

Provide Altman Z-Score Ratio
for OSE Immunotherapeutics SA.

Provide Quick Ratio
for OSE Immunotherapeutics SA.

Provide Current Ratio
for OSE Immunotherapeutics SA.

Provide Cash Ratio
for OSE Immunotherapeutics SA.

What is the historical Revenue growth
over the last 5 years for OSE Immunotherapeutics SA?

What is the historical Net Income growth
over the last 5 years for OSE Immunotherapeutics SA?

What is the current Free Cash Flow
of OSE Immunotherapeutics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for OSE Immunotherapeutics SA.

OSE

Cash Flow Statement

Net Issuance of Common Stock

OSE Immunotherapeutics SA
Net Issuance of Common Stock

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

Adjust for Inflation

OSE Immunotherapeutics SA
Net Issuance of Common Stock Peer Comparison

Comparables:

VLA

NANO

GNFT

IVA

ALERS

Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors

Company		Net Issuance of Common Stock	CAGR 3Y	CAGR 5Y	CAGR 10Y
	OSE Immunotherapeutics SA PAR:OSE	Net Issuance of Common Stock €11.1m	CAGR 3-Years -14%	CAGR 5-Years N/A	CAGR 10-Years N/A
	Valneva SE PAR:VLA	Net Issuance of Common Stock €57.5m	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
	Nanobiotix SA PAR:NANO	Net Issuance of Common Stock N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
G	Genfit SA PAR:GNFT	Net Issuance of Common Stock €0	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
	Inventiva SA PAR:IVA	Net Issuance of Common Stock €28.1m	CAGR 3-Years -31%	CAGR 5-Years 326%	CAGR 10-Years N/A
	Eurobio Scientific SA PAR:ALERS	Net Issuance of Common Stock -€2.8m	CAGR 3-Years 26%	CAGR 5-Years N/A	CAGR 10-Years N/A

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock?

Net Issuance of Common Stock
11.1m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Net Issuance of Common Stock amounts to 11.1m EUR.

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock growth rate?

Net Issuance of Common Stock CAGR 3Y
-14%

Over the last year, the Net Issuance of Common Stock growth was 2 148%. The average annual Net Issuance of Common Stock growth rates for OSE Immunotherapeutics SA have been -14% over the past three years .

OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Net Issuance of Common Stock

OSE Immunotherapeutics SA
Net Issuance of Common Stock Peer Comparison

Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors

See Also

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock?

Net Issuance of Common Stock
11.1m EUR

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock growth rate?

Net Issuance of Common Stock CAGR 3Y
-14%

Company

Help

Tools

Stocks

OSE Immunotherapeutics SA PAR:OSE

OSE Immunotherapeutics SA Net Issuance of Common Stock

OSE Immunotherapeutics SA Net Issuance of Common Stock Peer Comparison

Competitive Net Issuance of Common Stock Analysis Latest Figures & CAGR of Competitors

See Also

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock? Net Issuance of Common Stock 11.1m EUR

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock growth rate? Net Issuance of Common Stock CAGR 3Y -14%

Company

Help

Tools

Stocks

OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Net Issuance of Common Stock

OSE Immunotherapeutics SA
Net Issuance of Common Stock Peer Comparison

Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock?

Net Issuance of Common Stock
11.1m EUR

What is OSE Immunotherapeutics SA's Net Issuance of Common Stock growth rate?

Net Issuance of Common Stock CAGR 3Y
-14%